2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMOCompleted
Primary objectives- To investigate the safety and tolerability profile of hVEGF26-104/RFASE.- To determine the effective dose of hVEGF26-104/RFASE required to neutralize VEGF in serum, defined as a VEGF level below 9,0 pg/mL.Secondary objectives- To…